Background The RAID score is a patient-derived patient reported outcome measure (PROM), developed by a EULAR task force, that assesses the impact of RA on seven important domains. Responsiveness of the RAID score was assessed in the preliminary validation,¹ but more data is needed on the sensitivity to change, especially compared to other PROMs and other conventional outcome measures.

Objectives The objective of this study was to assess the changes in the RAID score in patients with early RA during the first six months of intensive DMARD treatment, and to evaluate the responsiveness of RAID after 3 months compared to other PROMs and conventional measures of disease activity.

Methods RA patients with short disease duration were followed in the 24 month treat-to-target strategy ARCTIC trial.² The responsiveness of the RAID score was evaluated by calculating the Standardised Response Mean (SRM) followed by the Relative Efficiency (RE) with respect to the Ritchie Articular Index. SRMs and RE were also calculated for other PROMs and clinical outcome measures. An SRM with absolute value above 0.80 was considered high.

Results 230 RA patients were included. The mean symptom duration was 7.09±5.40 (±SD) months, the baseline mean RAID score was 4.49±2.14. At the 3 month follow-up, the mean change score for RAID was −2.25±1.98 and the SRM was −1.13 (-1.33 to −0.96) (table 1).

The RAID score was more efficient in detecting change than the Ritchie Articular Index and also demonstrated relatively high efficiency in detecting change compared to other PROMs and clinical outcome measures (figure 1).

• Download figure
• Open in new tab
• Download powerpoint

Abstract SAT0725HPR – Figure 1

Relative efficiency to tender joint count (Ritchie Articular Index) of the various outcomes reflecting disease activity at 3 months follow-up (Ritchie Articular Index = reference with a relative efficiency of 1.00).

Conclusions The RAID score proved to be highly responsive to change in RA patients with short disease duration who followed a treat-to-target strategy. The RAID score was efficient in detecting change compared to other PROMs and conventional disease activity measures.

References [1] Gossec, et al. ARD2011;70:935–42.

[2] Haavardsholm, et al. BMJ2016;354:i4205, 2016.

Disclosure of Interest K. Holten: None declared, J. Sexton: None declared, T. K. Kvien: None declared, E. A. Haavardsholm Grant/research support from: Pfizer, UCB, Roche, MSD and AbbVie, A.-B. Aga: None declared